Q-omics provides the consensus-scored LAS1L profile across patient tissues and cancer cell-line models. LAS1L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LAS1L is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LAS1L protein abundance shows 34,729 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where LAS1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAS1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAS1L survival associations across molecular data types. LAS1L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAS1L RNA expression–survival associations across cancer types. High LAS1L expression shows unfavorable associations in UVM, MESO, LIHC and KICH, but favorable associations in KIRC and OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify UVM as the clearest survival context for LAS1L RNA expression.
This table summarizes LAS1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LAS1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAS1L shows higher tumor expression in KIRC, COAD, HNSC, LIHC, STAD and LUAD. The KIRC box plot shows higher LAS1L RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with LAS1L in patient tissues and cancer cell lines. In patient samples, LAS1L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LAS1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
